|
Market Closed -
Nasdaq
16:00:00 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 1.000 USD | -2.91% |
|
-1.96% | -4.76% |
Company Valuation: Phio Pharmaceuticals Corp.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 13.53 | 5.084 | 1.857 | 3.118 | 11.3 | 11.62 | - |
| Change | - | -62.43% | -63.48% | 67.92% | 262.46% | 2.78% | - |
| Enterprise Value (EV) | 13.53 | 5.084 | 1.857 | 3.118 | 11.3 | 11.62 | 11.62 |
| Change | - | -62.43% | -63.48% | 67.92% | 262.46% | 2.78% | 0% |
| P/E | -0.96x | -0.44x | -0.15x | -0.2x | -0.72x | -0.69x | -1.64x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0x | 2x | 0x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | -0x | -0.65x | -0.58x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.66x | -0.69x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -112.3 | -90.9 | -46.8 | -9.08 | -1.45 | -1.445 | -0.61 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | -9.223 | -18 | -19.9 |
| EBIT 1 | -13.51 | -11.46 | -10.82 | -7.387 | -9.22 | -17.5 | -16.85 |
| Net income 1 | -13.29 | -11.48 | -10.83 | -7.15 | -8.698 | -16.99 | -16.56 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 108.000 | 40.176 | 6.840 | 1.800 | 1.050 | 1.000 | 1.000 |
| Nbr of stocks (in thousands) | 125 | 127 | 271 | 1,732 | 10,764 | 11,617 | - |
| Announcement Date | 3/22/22 | 3/22/23 | 4/1/24 | 3/31/25 | 3/5/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.69x | - | - | - | 11.62M | |
| 21.73x | 7.77x | 15.61x | 1.37% | 74.41B | |
| 30.79x | 8.87x | 27.62x | 0.04% | 59.26B | |
| 32.79x | 5.89x | 17.64x | 0.99% | 47.14B | |
| 33.58x | 3.26x | 14.07x | -.--% | 42.91B | |
| -21.23x | 229.92x | -22.88x | -.--% | 44.13B | |
| 46.86x | 5.42x | 29.73x | -.--% | 40.79B | |
| 27.79x | 7.97x | 20.59x | 0.41% | 30.77B | |
| 33.94x | 7.26x | 18.84x | -.--% | 29.31B | |
| -66.62x | 12.77x | -65.09x | -.--% | 23.71B | |
| Average | 13.89x | 32.13x | 6.24x | 0.31% | 39.25B | |
| Weighted average by Cap. | 19.55x | 32.23x | 10.39x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PHIO Stock
- Valuation Phio Pharmaceuticals Corp.
Select your edition
All financial news and data tailored to specific country editions
